A pH-sensitive chitosan-tripolyphosphate hydrogel beads for controlled glipizide delivery

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 97 B, Issue 1, 2011, Pages 175-183

  Sun, Ping ^a,b   Li, Ping ^a,b   Li, Yu Min ^a,b   Wei, Qin ^a   Tian, Lin Hong ^a  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Digestive System Tumors   (China)

Author keywords

drug delivery properties; glipizide; hydrogel; pH sensitivity; swelling characteristics

Indexed keywords

CHITOSAN; CROSSLINKING; GELATION; HYDROGELS; PH SENSORS; SWELLING; TARGETED DRUG DELIVERY;

CONTROLLED DELIVERY; CONTROLLED RELEASE SYSTEMS; DELIVERY BEHAVIORS; GLIPIZIDE; IONIC GELATION METHOD; PH SENSITIVITY; SWELLING CHARACTERISTICS; SWELLING PROPERTIES;

CONTROLLED DRUG DELIVERY;

CHITOSAN DERIVATIVE; CHITOSAN TRIPOLYPHOSPHATE HYDROGEL BEAD; GLIPIZIDE; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED DRUG RELEASE; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; GELATION; HYDROGEL; INFRARED SPECTROSCOPY; PH; SCANNING ELECTRON MICROSCOPY;

EID: 79952434337     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31801     Document Type: Article

References (35)

1. Wild S, Roglic G, Green A, Sicree R, King H,. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053. (Pubitemid 38579764)
2. Hugh SM, Keeffe J, Fitzpatrick A, SiÃn A, Mullane MO, Perry I, Bradley C,; On behalf of the National Diabetes Register Project (NDRP) Diabetes care in Ireland. A survey of general practitioners. Prim Care Diabetes 2009; 3: 225-231.
3. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjörnsdõttir S,; for the Swedish National Diabetes Register (NDR). Pulse diabetes from the Swedish National Diabetes Register (NDR). Diabetes Metab 2009; 35: 439-446.
4. The Expert Committee on the Diagnosis. Classification of diabetes mellitus, report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
5. Alberti KG, Zimmet PZ,. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553. (Pubitemid 28319935)
6. McGill M, Felton AM,; On behalf of the Global Partnership for Effective Diabetes Management. New global recommendations: A multidisciplinary approach to improving outcomes in diabetes. Prim Care Diabetes 2007; 1: 49-55.
7. Hanas R, Ludvigsson J,. Side effects and indwelling times of subcutaneous catheters for insulin injections: a new device for injecting insulin with a minimum of pain in forthe treatment of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1990; 10: 73-83. (Pubitemid 20281519)
8. Bodo C, Melnik,. Permanent impairment of insulin resistancefrom pregnancy to adulthood: The primary basic risk factor of chronic Western diseases. Med Hypotheses 2009; 73: 670-681.
9. Ghoneim EM, El-Attar MA, Hammam E, Khashaba PY,. Stripping voltammetric quantification of the anti-diabetic drugGL in bulk form and pharmaceutical formulation. J Pharm Biomed Anal 2007; 43: 1465-1469. (Pubitemid 46282356)
10. Zhong P, Lin J, Daksha DK, Shum L,. Simultaneous determination of GL and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life 2004; 801: 265-272. (Pubitemid 38130076)
11. Verma RK, Garg S,. Development and evaluation of osmotically controlled oral drug delivery system of GL. Eur J Pharm Biopharm 2004; 57: 513-525. (Pubitemid 38490570)
12. Srinivas M, Udupa N, Kumar S, Agarwal S, Subramanian G, Ranjith AK,. GL matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies. Life Sci 2006; 79: 1568-1577. (Pubitemid 44301274)
13. Jain S, Saraf S,. Influence of processing variables and in vitro characterization of GL loaded biodegradable nanoparticles. Diabetes Metab Syndr 2009; 3: 113-117.
14. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA,. Comparative efficacy of a once-daily controlled-release formulation of GL and immediate-release GL in patients with NIDDM. Diabetes Care 1994; 17: 1460-1464. (Pubitemid 24369732)
15. Foster RH, Plosker GL,. Glipizide: A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics 2000; 18: 289-306.
16. Bao HQ, Li L, Zhang HB,. Influence of cetyltrimethylammonium bromide on physicochemical properties and microstructures of chitosan-TPP nanoparticles in aqueous solutions. J Colloid Interface Sci 2008; 328: 270-277.
17. Zhao L, Xu L, Mitomo H, Yoshii F,. Synthesis of pH-sensitive PVP/CM-chitosan hydrogels with improved surface property by irradiation. Carbohydr Polym 2006; 64: 473-480.
18. Lin WC, Yu DG, Yang MC,. pH-sensitive polyelectrolyte complex hydrogel microspheres composed of chitosan/sodium tripolyphosphate/dextran sulfate:swelling kinetics and drug delivery properties. Colloids Surf B Biointerfaces 2005; 44: 143-151.
19. Mi FL, Sung HW, Shyu SS,. Drug release from chitosan-alginate complex beads reinforced by a naturally occurring crosslinking agent. Carbohydr Polym 2002; 48: 61-72.
20. Muzzarelli RAA,. Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cell Mol Life Sci 1997; 53: 131-140. (Pubitemid 27365884)
21. Yang CH, Huang KS, Lin PW, Lin YC,. Using a cross-flow microfluidic chip and external crosslinking reaction for monodisperse TPP-chitosan microparticles. Sens Actuators B Chem 2007; 124: 510-516.
22. Gan Q, Wang T, Cochrane C, McCarron P,. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 2005; 44: 65-73. (Pubitemid 41111534)
23. Shu XZ, Zhu KJ,. A new approach to prepare tripolyphosphate/chitosan complex beadss for controlled drug delivery. Int J Pharm 2000; 201: 51-58. (Pubitemid 30364969)
24. Dai YN, Li P, Zhang JP, Wang FQ, Wei Q,. A novel pH sensitive N-succinyl chitosan/alginate hydrogel beads for nifedipine delivery. Biopharm Drug Dispos 2008; 29: 173-184. (Pubitemid 351722162)
25. Kılıc-arslan M, Baykara T,. The effect of the drug/polymer ratio on the properties of the verapamil HCl loaded microspheres. Int J Pharm 2003; 252: 99-109. (Pubitemid 36126618)
26. Sankalia MG, Mashru RC, Mashru JM, Sutariya VB,. Reversed chitosan-alginate polyelectrolyte complex for stability improvement of alpha-amylase: Optimization and physicochemical characterization. Eur J Pharm Biopharm 2007; 65: 215-232. (Pubitemid 46038077)
27. Chen SC, Wu YC, Mi FL, Lin YH, Yu LC, Sung HW,. A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J Control Release 2004; 96: 285-300.
28. Verma RK, Garg S,. Selection of excipients for extended release formulations of GL through drug-excipient compatibility testing. J Pharm Biomed Anal 2005; 38: 633-644. (Pubitemid 40835561)
29. Zhang H, Oh M, Allen C, Kumacheva E,. Monodisperse chitosan nanoparticles for mucosal drug delivery. Biomacromolecules 2004; 5: 2461-2468. (Pubitemid 39585302)
30. Jamzad S, Fassihi R,. Role of Surfactant and pH on dissolution properties of fenofibrate and glipizide-A technical note. AAPS PharmSciTech 2006; 7: E33.
31. Yan CY, Chen DW, Gu JW, Hu HY, Zhao XL, Qiao MX,. Preparation of N-succinyl-chitosan and their physical-chemical properties as a novel excipient. Pharm Soc Japan 2006; 126: 789-793.
32. Xi FN, Wu JM, Jia ZS, Lin XF,. Preparation and characterization of trypsin immobilization on silica gel supported macroporous chitosan beads. Process Biochem 2005; 40: 2833-2840.
33. Qiu Y, Park K,. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001; 53: 321-339. (Pubitemid 34024913)
34. Kang XH, Mai ZB, Zou ZY, Cai PX, Mo JY,. A novel glucose biosensor based on immobilization of glucose oxidase in chitosan on a glassy carbon electrode modified, with gold-platinum alloy nanoparticles/multiwall carbon nanotubes. Anal Biochem 2007; 369: 71-79.
35. Ravaine V, Ancla C, Catargi B,. Chemically controlled closed-loop insulin delivery. J Control Release 2008; 132: 2-11.